Vaxart, Inc. Stock News

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart's oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The sentinel cohort comprised of 400 participants, with 200 receiving Vaxart's COVID-19 vaccine candidate and 2...

Vaxart, Inc. (NASDAQ:VXRT ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Senior Vice President and Chief Scientific Officer Phillip Lee - Chief Financial Officer Conference Call Participants Cheng Li - Oppenheimer ...

Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.

— 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart's next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator —

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 32,250 shares of its common stock to two new non-executive employees to induce them to accept employment with Vaxart.

Vaxart, Inc. (NASDAQ:VXRT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ed Berg - SVP & General Counsel Steven Lo - CEO Sean Tucker - Founder & Chief Scientific Officer James Cummings - Chief Medical Officer Phil Lee - CFO Conference Call Participants Elaine Kim - Cantor Fitzgerald Operator Greetings and welcome to the Vaxart Business Update and Second Quarte...

BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart's oral pill vaccine platform as a next-generation approach to combating COVID-19 and future pandemic threats

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.